A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN.
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2011
At a glance
- Drugs AZD 4877 (Primary)
- Indications Acute myeloid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 05 Sep 2007 Status changed from recruiting to discontinued.
- 22 Jun 2007 New trial record.